Handelsavisen
prelaunch
Companies ›Healthcare ›300841.SZ
30
300841.SZ — Shenzhen Stock Exchange Pharmaceuticals

Chengdu Kanghua Biological Products Co Ltd

¥52,49
Open in Charts → Attach watcher ⌖
— —
CNY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
1,75 %
Op margin
22,3 %
ROE
6,2 %
Net margin
18,9 %
Debt / equity
0,04
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Chengdu Kanghua Biological Products Co Ltd is a biotechnology company focused on the research, development, and commercialization of biological products, primarily in the healthcare sector.

Business. Chengdu Kanghua Biological Products Co Ltd (300841.SZ) is a pharmaceutical company headquartered in Chengdu, operating within the Healthcare sector. The firm is primarily engaged in pharmaceuticals and medical research activities. It is listed on the Shenzhen Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target—

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
—
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
1 analysts · indicative
Ownership
—
not yet wired
Profitability→
6,2 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 300841.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 300841.SZ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Chengdu Kanghua Biological Products Co Ltd (300841.SZ) is a pharmaceutical company headquartered in Chengdu, operating within the Healthcare sector. The firm is primarily engaged in pharmaceuticals and medical research activities. It is listed on the Shenzhen Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Chengdu Kanghua Biological Products Co Ltd maintains a strong capital structure with a debt-to-equity ratio of 0.04, indicating a low reliance on debt financing. The company's liquidity position is characterized by a current ratio of 5.74, suggesting a robust ability to meet short-term obligations. However, the risk assessment highlights a medium liquidity risk, with a note that net cash is negative after subtracting total debt.

    In terms of profitability, the company's return on equity (ROE) is 6.22%, and its return on assets (ROA) is 5.48%. These figures are below the industry median for ROE and ROA in the biotechnology sector, indicating that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization.

    The company's revenue is primarily concentrated in its core biotechnology segment, with no significant geographic diversification disclosed in the available data. This concentration may expose the company to higher operational and market risks if demand for its products fluctuates or if regulatory changes impact the biotechnology sector in its primary market.

    Looking ahead, the company's growth trajectory is expected to remain stable, with no significant revenue growth projected in the next fiscal year. The company's operating cash flow of 379.71 million CNY and free cash flow of 113.39 million CNY suggest that it has the capacity to fund operations and potentially invest in future growth.

    The risk assessment indicates a low dilution risk, with no immediate pressure for share issuance or dilution. However, the company's capital expenditure of -70.79 million CNY suggests that it is currently reducing its investment in physical assets, which may affect its long-term growth potential.

    Recent events and filings do not indicate any material changes in the company's operations or financial position. The company's latest earnings per share (EPS) of 1.69 CNY is below the mean analyst estimate of 3.07 CNY, suggesting that the company may be underperforming relative to expectations.

    Key takeaways
    • The company has a strong liquidity position with a current ratio of 5.74 but faces medium liquidity risk due to negative net cash after debt.
    • ROE and ROA are below industry medians, indicating underperformance in capital efficiency and asset utilization.
    • Revenue is concentrated in a single segment, increasing exposure to market and regulatory risks.
    • No significant revenue growth is expected in the next fiscal year, and capital expenditures are currently negative.
    • Analysts have a neutral outlook, with one "buy" recommendation and no "strong buy" or "sell" ratings.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥52,49
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    ¥3.54B
    Net cashⓘ
    -¥139.8M
    Current ratioⓘ
    5.7
    Debt / equityⓘ
    0.0
    ROAⓘ
    5.5%
    ROEⓘ
    6.2%
    Cash conversionⓘ
    173.0%
    CapEx / revenueⓘ
    -6.1%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    3,07
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-05-21 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate3,07
    Revenue—no estimate—no estimate1,5B CNY
    Operating income—no estimate—no estimate—no estimate
    Full-year consensus mean (period as reported by source) · consensus in CNY. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    EPS surprise
    −44,9 %
    reported vs consensus · miss
    Revenue surprise
    −20,4 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin22,3 %Above P75
    Net Margin18,9 %Above P75
    ROE6,2 %Above median
    Capex / Rev-6,1 %Below median
    D/E0,04Above median
    Cash Conv1,73Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Chengdu Kanghua Biological Products Co Ltd Market data — financials · 2026-05-26
    • Chengdu Kanghua Biological Products Co Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Leadership

    • Changyong FanExecutive Vice President

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    300841.SZCanonical
    Shenzhen Stock Exchange · CNY

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage